Duality Advisers LP Acquires New Stake in R1 RCM Inc. (NASDAQ:RCM)

Duality Advisers LP acquired a new stake in R1 RCM Inc. (NASDAQ:RCM) during the 4th quarter, Holdings Channel reports. The fund acquired 45,975 shares of the healthcare provider’s stock, valued at approximately $486,000.

Several other institutional investors have also added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its position in R1 RCM by 5.6% in the 3rd quarter. Vanguard Group Inc. now owns 17,940,792 shares of the healthcare provider’s stock valued at $270,368,000 after acquiring an additional 947,310 shares in the last quarter. Voss Capital LLC increased its stake in R1 RCM by 553.9% in the 4th quarter. Voss Capital LLC now owns 7,125,000 shares of the healthcare provider’s stock valued at $75,311,000 after buying an additional 6,035,340 shares during the last quarter. Bank of New York Mellon Corp increased its stake in R1 RCM by 3.4% in the 3rd quarter. Bank of New York Mellon Corp now owns 7,017,700 shares of the healthcare provider’s stock valued at $105,757,000 after buying an additional 229,104 shares during the last quarter. Invesco Ltd. increased its stake in R1 RCM by 4.4% in the 3rd quarter. Invesco Ltd. now owns 5,120,817 shares of the healthcare provider’s stock valued at $77,171,000 after buying an additional 218,100 shares during the last quarter. Finally, Polar Capital Holdings Plc increased its stake in R1 RCM by 0.5% in the 3rd quarter. Polar Capital Holdings Plc now owns 4,696,412 shares of the healthcare provider’s stock valued at $70,775,000 after buying an additional 22,550 shares during the last quarter. 61.10% of the stock is owned by institutional investors.

R1 RCM Stock Performance

Shares of RCM opened at $11.82 on Friday. R1 RCM Inc. has a 52 week low of $8.87 and a 52 week high of $18.70. The firm’s 50-day simple moving average is $12.81 and its 200 day simple moving average is $11.47. The company has a current ratio of 1.83, a quick ratio of 1.83 and a debt-to-equity ratio of 0.57.

Analysts Set New Price Targets

Several brokerages have issued reports on RCM. Leerink Partnrs reiterated an “outperform” rating on shares of R1 RCM in a research note on Monday, February 26th. Evercore ISI reiterated an “in-line” rating and issued a $16.00 price target (up from $12.00) on shares of R1 RCM in a research note on Wednesday, February 28th. Barclays reiterated an “equal weight” rating and issued a $14.00 price target on shares of R1 RCM in a research note on Wednesday, February 28th. Guggenheim lowered their price objective on shares of R1 RCM from $17.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, April 5th. Finally, Citigroup upgraded shares of R1 RCM from a “neutral” rating to a “buy” rating and set a $16.00 price objective on the stock in a research note on Wednesday, March 20th. Five research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, R1 RCM currently has a consensus rating of “Moderate Buy” and a consensus target price of $16.87.

Insider Activity at R1 RCM

In related news, President John M. Sparby sold 10,046 shares of the company’s stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $14.33, for a total value of $143,959.18. Following the transaction, the president now owns 265,986 shares in the company, valued at approximately $3,811,579.38. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 36.80% of the stock is owned by company insiders.

R1 RCM Profile

R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.